The newspaper referred in an editorial to these demands by the laboratory to sell their vaccine and considered “understandable” that they have not been accepted.
The American newspaper The New York Times recently referred in an editorial to the excessive demands made by the Pfizer laboratory to some countries to sell them its vaccine against the coronavirus and considered it “understandable” that they have resisted accepting them.
Although the US pharmaceutical giant’s vaccine is the second most approved worldwide, behind AstraZeneca‘s, several countries were unable to acquire it due to disagreements when closing contracts.
“Pfizer has reportedly not only sought liability protection against all civil claims, even those that could result from the company’s own negligence, but has asked governments to contribute sovereign assets, including its bank reserves, buildings of embassies and military bases, as a guarantee against lawsuits, ” said the US newspaper in an opinion article.
“It is understandable that some countries have resisted such demands, ” he noted, adding, ” and the pace of purchase agreements has slowed as a result.”
In the note, the US newspaper cites the report published last February by the British organization Bureau of Investigative Journalism, which refers to the accusations made against Pfizer of “intimidating” Latin American governments, including Argentina and Brazil, in the negotiations to purchase your coronavirus vaccine.
According to the Covid-19 Vaccine Tracker portal, Pfizer’s vaccine is preferred by higher-income nations, especially in the United States, as they are manufactured locally.